Search results
Showing 1 to 15 of 16 results for semaglutide for weight management
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.
Show all sections
Sections for NG246
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Major changes to type 2 diabetes treatment could save thousands of lives
New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
NICE recommended weight-loss drug to be made available in specialist NHS services
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.